Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

eea52742.e0f3.48e7.87b0.14afc03a5046

· cohortMD2

b120f78d-ee7c-5a59-a87f-a4c0fbaaf1da

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortMD2
subtype
cohortMD2
age_years
57

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.330
  • G2M_CHECKPOINT+0.220
  • INTERFERON_ALPHA_RESPONSE+0.220
  • MITOTIC_SPINDLE+0.190
  • DNA_REPAIR+0.150
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.070
  • MYC_TARGETS_V1+0.050
  • NOTCH_SIGNALING+0.050
  • COMPLEMENT+0.040
  • GLYCOLYSIS+0.040

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.440
  • ESTROGEN_RESPONSE_EARLY-0.360
  • CHOLESTEROL_HOMEOSTASIS-0.350
  • ESTROGEN_RESPONSE_LATE-0.340
  • OXIDATIVE_PHOSPHORYLATION-0.340
  • UNFOLDED_PROTEIN_RESPONSE-0.340
  • ADIPOGENESIS-0.330
  • FATTY_ACID_METABOLISM-0.330
  • MTORC1_SIGNALING-0.330
  • ANDROGEN_RESPONSE-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR6013553
lung-landscapes@6
cohortA30.806
2MNG357
mng-umap@100
0.798
3SRR1313133
breast-umap@18
D0.772
4BS_9FHSNVS0
brain-umap@2
ATRT0.747
5SRR8613722
breast-umap@18
E0.736
6c01b5135.b754.4c57.a81d.68a951803fab
lung-landscapes@6
cohortMD10.735
7MNG182
mng-umap@100
0.732
8TCGA-98-A53I-01A-31R-A262-07
lung-landscapes@6
cohortSQ20.726
983486
medullo-epn-umap@date-based
EPNSupratentorial EPN0.720
10SAMN03290905
melanoma-umap@29
0.719

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.330Inavolisib— uncovered
G2M_CHECKPOINT0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.220Inavolisib— uncovered
MITOTIC_SPINDLE0.190Inavolisib— uncovered
DNA_REPAIR0.150Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.070Inavolisib— uncovered
MYC_TARGETS_V10.050Inavolisib— uncovered
NOTCH_SIGNALING0.050Inavolisib— uncovered
COMPLEMENT0.040Inavolisib— uncovered
GLYCOLYSIS0.040Inavolisib— uncovered